Normative Radiographic Parameters and Growth Curve of Hips Less Than Six Weeks of Gestational Age Using Ultrasound
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Apr 6, 2017
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying hip dysplasia, a condition where a baby's hip joint doesn't develop correctly. Researchers want to gather information about how healthy hips look in newborns aged 32 to 46 weeks, using ultrasound technology. The goal is to create a growth chart that will help doctors better understand and treat hip dysplasia in infants.
To participate, babies born at CRMC, whether they are full-term or premature, can join the study. This includes newborns from the hospital's regular maternity ward or the neonatal intensive care unit (NICU). However, babies with certain conditions, like known genetic issues that affect the hips or immediate treatment needs for dislocated hips, will not be eligible. If your baby joins the study, they will undergo a simple ultrasound that will help gather important information for future treatments. This research aims to improve care for infants with hip dysplasia and is currently looking for participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age.
- • newborns in NICU
- • newborns on postpartum floor
- • single birth
- • multiple births
- • normal presentation
- • breach presentation
- Exclusion Criteria:
- • known neuromuscular or genetic condition predisposing infant to hip dysplasia (i.e. Spina Bifida, Cerebral Palsy),
- • inability to follow up (i.e. doesn't live in surrounding area),
- • frankly dislocated hips that require immediate treatment,
- • any medical condition precluding safe hip ultrasound.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fresno, California, United States
Patients applied
Trial Officials
John Wiemann, MD
Principal Investigator
UCSF - Fresno
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials